However, data from the International Cancer Genome Consortium, indicate a low incidence (2.15%) of B2M mutations in ovarian cancer tissues, while the frequency was much higher in germinal center B cell lymphomas (19%) and melanoma (11.43% and 13.6%, in two different projects) (https://dcc.icgc.org/genes/ENSG00000166710). This evidence concerns the gene B2M and melanoma.